Thu, 28/09/2017 - 08:30
London, UK, 28th September 2017 / Sciad Newswire / The US approval of Novartis's  Kymriah for childhood leukaemia opens a dramatic new era of cancer therapy deplo
Wed, 27/09/2017 - 07:30
Coventry, UK, 27th September 2017 / Sciad Newswire / Medherant, a leader in next-generation transdermal drug delivery, has s
Tue, 26/09/2017 - 00:15
New approach informed by government priorities, consultancy with industry and the NHS, and a century of expertise
Wed, 20/09/2017 - 07:30
Edinburgh, UK, 20th September 2017 / Sciad Newswire / Synpromics Ltd, the leader in gene control, today announces a new r
Mon, 18/09/2017 - 07:30
Cambridge, UK, 18th September 2017 / Sciad Newswire / Cypralis, a life sciences company focused on the discovery of therape
Tue, 12/09/2017 - 08:00
Poster and Oral Presentation at the 19th RSC / SCI Medicinal Chemistry Symposium, 10th-13th September 2017, Churchill College, Cambridge, UK
The Roslin Innovation Centre
Mon, 11/09/2017 - 07:30
Edinburgh, UK, 11th September 2017 / Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the
Tue, 05/09/2017 - 07:30
Challenge trial will evaluate RV521 in approximately 70 volunteers
Wed, 30/08/2017 - 15:30
London, UK, 25th August 2017 / Sciad Newswire / Touchlight Genetics Ltd has developed a revolutionary DNA technology that can synthetically manufacture commercial
Thu, 29/06/2017 - 07:30
Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.